Cite

HARVARD Citation

    Askar, S. et al. (2023). Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection With a Focus on Immunocompromised Patients. Journal of pharmacy practice. pp. 584-587. [Online]. 
  
Back to record